Background & Aim: The relationship between obesity and hepatic steatosis is well known, and there are many methods to measure obesity and severity of hepatic steatosis. Because of advances in radiologic techniques, the areas of certain body components can be measured on computed tomography (CT) while the severity of hepatic steatosis can be measured by magnetic resonance spectroscopy (MRS) with high accuracy. The aim of this study is to investigate the relationship between degree of fatty infiltration of the liver measured by MRS and body composition measured from CT images.
Materials And Methods: We evaluated 95 potential liver donors who underwent abdomen CT and liver MRI (including MRS) between February 2014 and September 2015 in a tertiary university hospital. Body composition analysis was performed on CT images using commercial software. The areas of subcutaneous fat, visceral fat and abdominal circumference were measured automatically and the area of muscle was measured semi-automatically. The degree of hepatic steatosis was measured by MRS.
Results: The degree of hepatic steatosis showed a significant correlation with total fat area, visceral fat area, subcutaneous fat area, muscle area, abdominal circumference, BMI, and ratio of visceral fat to total fat. The strongest correlation was between hepatic steatosis and the area of visceral fat in all subjects (r=0.569). Multivariate regression analysis showed that male gender and visceral fat area were significantly associated with hepatic steatosis (P = 0.031, <0.001, respectively).
Conclusions: The area of visceral fat has the most intimate correlation to the severity of hepatic steatosis among all significantly correlated parameters associated with body habitus. Accurate and quantitative body composition measurement and degree of hepatic steatosis can be noninvasively performed using advanced radiological techniques.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clnu.2016.12.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pumpkin Soluble Dietary Fiber instead of Insoluble One Ameliorates Hyperglycemia via the Gut Microbiota-Gut-Liver Axis in db/db Mice.
J Agric Food Chem
January 2025
College of Food Science and Engineering, Northwest A&F University, Yangling, 712100 Shaanxi, China.
Pumpkin extract has been shown to alleviate hyperglycemic symptoms by improving glucose metabolism disorders. However, the specific active components responsible for its hypoglycemic effects and the underlying molecular mechanisms remain unclear. In this study, db/db mice underwent a 4-week dietary intervention with two pumpkin flours (PF1 and PF2), total dietary fiber (TDF), soluble dietary fiber (SDF), and insoluble dietary fiber (IDF), with acarbose serving as a positive control.
View Article and Find Full Text PDFPredicting colorectal adenomatous polyps in patients with chronic liver disease: A novel nomogram.
World J Gastroenterol
January 2025
Clinical School of the Second People's Hospital, Tianjin Medical University, Tianjin 300192, China.
Background: Colorectal polyps are commonly observed in patients with chronic liver disease (CLD) and pose a significant clinical concern because of their potential for malignancy.
Aim: To explore the clinical characteristics of colorectal polyps in patients with CLD, a nomogram was established to predict the presence of adenomatous polyps (AP).
Methods: Patients with CLD who underwent colonoscopy at Tianjin Second People's Hospital from January 2020 to May 2023 were evaluated.
Prospects of elafibranor in treating alcohol-associated liver diseases.
World J Gastroenterol
January 2025
School of Basic Medicine, Qilu Medical University, Zibo 255300, Shandong Province, China.
Alcohol-related liver disease (ALD), which is induced by excessive alcohol consumption, is a leading cause of liver-related morbidity and mortality. ALD patients exhibit a spectrum of liver injuries, including hepatic steatosis, inflammation, and fibrosis, similar to symptoms of nonalcohol-associated liver diseases such as primary biliary cholangitis, metabolic dysfunction-associated steatotic liver disease, and nonalcoholic steatohepatitis. Elafibranor has been approved for the treatment of primary biliary cholangitis and has been shown to improve symptoms in both animal models and cell models of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis.
View Article and Find Full Text PDFGinsenoside, a potential natural product against liver diseases: a comprehensive review from molecular mechanisms to application.
Crit Rev Food Sci Nutr
January 2025
Shaanxi Key Laboratory of Degradable Biomedical Materials, Shaanxi R&D Center of Biomaterials and Fermentation Engineering, Biotech & Biomed Research Institute, School of Chemical Engineering, Northwest University, Xi'an, China.
Liver disease constitutes a significant cause of global mortality, with its pathogenesis being multifaceted. Identifying effective pharmacological and preventive strategies is imperative for liver protection. Ginsenosides, the major bioactive compounds found in ginseng, exhibit multiple pharmacological activities including protection against liver-related diseases by mitigating liver fat accumulation and inflammation, preventing hepatic fibrosis, and exerting anti-hepatocarcinogenic effects.
View Article and Find Full Text PDFAssociation of changes in the type 2 diabetes and MASLD/related SLD status with risk of developing cardiovascular disease.
Diabetes Obes Metab
January 2025
Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Background & Aims: This study assessed the association of remission of type 2 diabetes mellitus (DM) or metabolic dysfunction-associated steatotic liver disease (MASLD)/related SLD (r-SLD; MASLD with excessive alcohol intake) as defined by the fatty liver index with the risk of cardiovascular disease (CVD).
Methods: Health examination data at baseline and after 2 years (2-Years) were extracted from a nationwide claims database in Japan. Among participants aged 18-72 years with at least 3 years of follow-up, 9345 participants with DM-associated MASLD/r-SLD and 71 932 participants with non-DM MASLD/r-SLD at baseline were included in the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!